Ofloxacin was used in the empirical and etiotropic therapy of patients with severe urinary tract infection. The trial was based on the previous experience with ofloxacin in the treatment of various forms of urological infection with determination of the pathogen susceptibility and study of the drug pharmacokinetics in patients with normal and impaired renal function. For the first 3 to 5 days in the present study ofloxacin was administered in a dose of 200 mg twice a day followed by its oral use in the same dosage for 3 to 5 days. The treatment schemes were corrected by the bacteriological findings (mainly when Pseudomonas aeruginosa strains were isolated). The results of the treatment of more than 200 patients showed that ofloxacin was highly efficient. By the clinical and bacteriological indices the drug proved to be efficient in 96 and 88 per cent of the cases respectively. In the treatment of patients with noncomplicated urinary tract infection good results (the clinical and bacteriological efficacies of 96 and 88 per cent respectively) were observed when ofloxacin was used orally in a single dose of not more than 400 mg once a day for 3 to 5 days. In the patients with chlamydiosis the drug was used in the same dosage for 10 days. Ofloxacin was also shown to be highly efficient when used prophylactically in transurethral surgical operations on the prostate and in open urological operations.
Download full-text PDF |
Source |
---|
Int Ophthalmol
December 2024
University of Medicine and Pharmacy, Ho Chi Minh City, Vietnam.
Background: The increasing drug resistance of Pseudomonas aeruginosa (PA) poses a serious challenge to the current treatment. Antibiograms of this pathogen often take 3-5 days, and treatment of Pseudomonas aeruginosa keratitis (PAK) is mainly based on preliminary physical examination, clinical experience, and medical guidelines. Pertinent clinical data on the causative agent and antibiotics for high efficacy are essential for early recognition and subsequent treatment.
View Article and Find Full Text PDFPLoS Negl Trop Dis
December 2024
Hospital for Tropical Diseases, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
Introduction: The World Health Organization (WHO) recommends rifampicin, dapsone and clofazimine multi-drug therapy (MDT) for the treatment of leprosy. Severe adverse effects include dapsone hypersensitivity syndrome, skin pigmentation, haemolytic anaemia, and hepatitis. At the Hospital for Tropical Diseases (HTD), London, United Kingdom monthly rifampicin, ofloxacin and minocycline (mROM) is used as first line treatment for leprosy.
View Article and Find Full Text PDFFront Immunol
December 2024
Fourth Department of Critical Care Medicine, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, Fujian, China.
Invasive aspergillosis (IA) significantly increases mortality in critically ill patients in the ICU and its occurrence is closely related to immunocompromise. Dissemination of IA is easily misdiagnosed and mistreated due to its ability to invade multiple systems throughout the body and lack of typical clinical manifestations. In this case, a 25-year-old previously healthy woman was hospitalized with fulminant myocarditis and treated with veno-arterial extracorporeal membrane pulmonary oxygenation (VA-ECMO) support and intravenous acyclovir, high-dose methylprednisolone, and immunoglobulin.
View Article and Find Full Text PDFFr J Urol
December 2024
Department of Urology, Saint Louis Hospital, Paris-Cite University, Paris, France.
Introduction: Adjuvant treatment with endovesical BCG instillations after resection of a bladder urothelial tumor remains the gold standard for intermediate- or high-risk non-muscle-invasive tumors. However, it is associated with frequent and sometimes serious adverse events (AEs).
Objectives: To comprehensively assess the frequency, intensity, and potential risk factors of BCG instillation AEs following the field experience of a single French center using only the Medac® BCG.
Microbiol Spectr
November 2024
Department of Clinical Laboratory, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, Zhejiang, China.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!